Home › MDNA Moves Into Liquid Biopsy Market With New Prostate Cancer Test

MDNA Moves Into Liquid Biopsy Market With New Prostate Cancer Test

Dec 02, 2016
|
Molika Ashford
Premium

NEW YORK (GenomeWeb) – Mitochondrial DNA diagnostics firm MDNA Life Sciences announced the launch of its first noninvasive blood-based cancer test this week, with Phi Life Sciences as the assay's first US distributor.

Though the company got its start developing assays for analysis of tissue samples, researchers have more recently found that the firm's mitochondrial DNA-based approach is similarly sensitive when applied to blood samples. Based on this, the company has now shifted its focus to the liquid biopsy space.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

What's Popular?

In Molecular Diagnostics

  1. Danaher Q2 Revenues Grow 6 Percent; MDx Product Line Shut Down

  2. Startup SpinDiag Raises €1.6M in Seed Funding

  3. Courtagen Closes Genetic Testing Business, Citing Regulatory, Reimbursement Challenges

  4. NanoVelcro Microchips Can Capture Fetal Cells from Maternal Blood for Prenatal Genetic Testing

    Premium

  5. Abbott Dx Revenues Rise 4 Percent in Q2 on Strong Core Lab and Point-of-Care Growth

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.